Professor Aleksander Krag explains that while a third of adults have fatty liver, the fat itself is harmless—it’s scarring (fibrosis) that predicts liver disease. He breaks down simple, non-invasive tests like FIB-4 and FibroScan that catch fibrosis early and reveals how blood-based alcohol biomarkers expose hidden drinking. The conversation also covers liver damage reversibility, emerging drugs like semaglutide, and the policy changes Krag argues would do more than any clinic.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Highlights
•
Steatosis vs Fibrosis: Fat Is Not the Danger
Professor Krag explains that while 30% of people have fatty liver (steatosis), the fat itself is benign; it’s scarring (fibrosis) that predicts liver disease.
Policy Levers Over Pills for Liver Disease Prevention
Krag argues that population-level interventions like alcohol pricing and food environment changes would prevent more liver disease than clinical treatment.